Resources
67 Results (showing 1 - 10)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 6/7/2022 (updated 3/27/2024)
Cohort-Specific Sessions/Activities and Day 2 Wrap-Up
Posted 6/7/2022 (updated 3/27/2024)
Dr. Brooklyn discussed the following topics: the implementation of a Hub and Spoke model can lead to a significant increase in number of people with OUD treated in rural areas by providing resources for small and rural medical and behavioral health practices and a novel program to increase dosing compliance and security through the use of secure medication dispensers and a Smartphone app can increase access to MOUD in rural areas.
Posted 6/7/2022 (updated 3/27/2024)
This session highlighted the ways in which data from RCORP consortia are used, how service capacity and access have changed, and whether there is evidence that the health status of rural residents is improving. Additional data on telehealth utility, COVID-19 vaccination efforts, and drivers of MAT retention were highlighted. (Repeated from Day 1 Session 4A on Tuesday, April 5th).
Posted 6/6/2022 (updated 3/27/2024)
There are many pathways of recovery from substance use disorder, and all are cause for celebration. This panel featured diverse faces and voices representing a variety of recovery experience including elements of medications for opioid use disorder, alcohol-free recreation, harm reduction mutual aid, outdoor hobbies, yoga and meditation, recovery-supportive housing, collegiate recovery, 12-step mutual aid, and more.
Posted 6/3/2022 (updated 3/27/2024)
This session highlighted the ways in which data from RCORP consortia are used, how service capacity and access have changed, and whether there is evidence that the health status of rural residents is improving. Additional data on telehealth utility, COVID-19 vaccination efforts, and drivers of Medication-Assisted Treatment (MAT) retention was highlighted.
Posted 10/3/2022 (updated 3/27/2024)
The United States overdose crisis continues unabated. Despite efforts to increase capacity for treating opioid use disorder (OUD) in the U.S., how actual treatment receipt compares to need remains unclear. In this cross-sectional study, progress is estimated in addressing the gap between OUD prevalence and OUD treatment receipt at the national and state levels from 2010 to 2019.
Posted 8/2/2022 (updated 3/27/2024)
Innovative at their inception three decades ago, drug courts confront a practical and ethical obligation to reimagine some core practices and assumptions. A shifting legal and public health landscape means, for example, increased scrutiny of the courts’ focus on abstinence and mandated treatment, and the use of jail. This publication argues the most effective way for drug courts to evolve is by integrating the practices and principles of harm reduction
Posted 10/12/2023 (updated 3/27/2024)
Posted 3/15/2022 (updated 3/27/2024)
Pre- Pregnancy fact sheet. Information for Providers
Posted 3/15/2022 (updated 3/27/2024)
This TIP reviews three Food and Drug Administration-approved medications for opioid use disorder treatment—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support people in recovery.